2026-04-29T00:59:39Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/182552024-11-28T15:49:14Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16958col_20.500.12105_16988
Repisalud author Martínez-Trufero, Javier author De Sande-González, Luis Miguel author Luna, Pablo author Martin-Broto, Javier author Álvarez, Rosa author Marquina, Gloria author Diaz-Beveridge, Roberto author Poveda, Andrés author Cano, Juana María author Cruz-Jurado, Josefina author López Pousa, Antonio author Vaz Salgado, María Angeles author Valverde-Morales, Claudia M. author Sevilla, Isabel author Martínez-García, Jerónimo author Rubio-Casadevall, Jordi author De Juan, Ana author Carrasco, Juan Antonio author Moura, David S. author Gurruchaga-Sotes, Ibon author Gutiérrez, Antonio authoraffiliation [Martínez-Trufero,J; Gurruchaga-Sotes,I] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González,LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna,P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto,J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS; CSIC, US, HUVR), Sevilla, Spain. [Álvarez,R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina,G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Diaz-Beveridge,R] Medical Oncology Department, Hospital Politécnico La Fe, Valencia, Spain. [Poveda,A] Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia, Spain. [Cano,JM] Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. [Cruz-Jurado,J] Medical Oncology Department, Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain. [López Pousa,A] Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. [Vaz Salgado,MA] Medical Oncology Department, Hospital Universitario Ramon y Cajal, RYCIS, CIBERONC, Madrid, Spain. [Valverde-Morales,C] Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain. [Sevilla,I] Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Medical Oncology Department, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain. [Martínez-García,J] Medical Oncology Department, Hospital Virgen de la Arrixaca, Murcia, Spain. [Rubio-Casadevall,J] Medical Oncology Department, Instituto Catalan Oncologia, Girona, Spain. [De Juan,A] Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain. [Carrasco,JA] Medical Oncology Department, Hospital Alvaro Cunqueiro, Vigo, Spain. [Moura,DS] Instituto de Biomedicina de Sevilla (IBiS; CSIC, US, HUVR), Sevilla, Spain. [Gutiérrez,A] Hematology Department, Hospital Universitario Son Espases, 07010 Palma de Mallorca, Spain. 2024-02-19T15:25:02Z 2024-02-19T15:25:02Z 2021-02-14 http://hdl.handle.net/10668/4498 http://hdl.handle.net/20.500.12105/18255 33672857 10.3390/cancers13040792 2072-6694 Cancers The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS. eng Trabectedin Sarcoma Growth modulation index Prognostic score L-sarcoma GEISTRA Spain Advanced soft tissue sarcomas Trabectedina Pronóstico Liposarcoma Leiomiosarcoma España A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study research article